^
Association details:
| Biomarker: | ALK wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Yidafan (ivonescimab) (PD1 inhibitor, VEGF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer
Published date:
05/26/2022
Excerpt:
...in cohort-1, among 26 evaluable pts with squamous cell carcinoma, 20 partial response and 6 stable disease were observed for a 76.9% ORR and a 100.0% DCR, median DOR and median PFS was not reached while 6-month PFS rate was 86.2%. In Cohort-2, among 19 evaluable pts, 13 partial response and 5 stable disease were observed for a 68.4% ORR and a 94.7% DCR while median DOR was 5.5 months, and median PFS was 8.3 months. AK112 plus chemotherapy has shown a promising anti-tumor efficacy in each cohort.
Secondary therapy:
carboplatin; pemetrexed; paclitaxel
DOI:
10.1200/JCO.2022.40.16_suppl.9019
Trial ID:
